Alexa Ball

Email me




Pasadena, California,

United States


Fuzionaire Diagnostics (“Fuzionaire Dx”) is a radiopharmaceutical company. Our radiolabeling platform aims to unlock the power of PET to help detect and treat any disease.

The primary barriers to better imaging are the result of basic limitations in chemistry. Leveraging a breakthrough in alkali metal catalysis, Fuzionaire Dx is working to radically improve the scope, safety, use, and cost of PET imaging.

Our patented HetSiFA™ compositions, which are synthesized using our alkali metal catalysts, can bioconjugate to disease-targeting ligands at record-breaking speed.

We make it possible to rapidly produce a broad range of fluorine-18 radiopharmaceuticals using a single catalyst-driven, disease-agnostic platform. Our technology offers researchers and clinicians a new strategy to detect, localize, diagnose, and monitor more diseases, earlier, and with unprecedented precision. The platform also has the potential to become a unique tool for drugmakers, providing critical in vivo pharmacological data earlier in the drug discovery process.

Fuzionaire Dx was co-founded by a team including CEO Nick Slavin, Chief Science Officer Anton Toutov, PhD, and Nova Spivack, and is advised by leading researchers in nuclear medicine and drug discovery.

For more, visit us at:


Nick slavin

Nick Slavin

Co-Founder and CEO

Mr. Slavin is the founder of EES Ventures, a venture capital firm focusing on seed-stage technologies out of universities, and founder and chairman of the Slavin Family Foundation, which operates a fellowship supporting world-changing student entrepreneurs. He is also a co-founder with Mr. Spivack of the Arch Mission Foundation, a nonprofit creating multiple redundant repositories of human knowledge in space, which created the first permanent library in solar orbit in February 2018 as part of SpaceX’s Falcon Heavy test launch. Previously, Mr. Slavin spent seven years as a corporate attorney at Norton Rose Fulbright and Skadden Arps, at the time the #1 ranked corporate law firm by Corporate Board Member magazine for 13 consecutive years. Mr. Slavin is an advisor at the Texas Medical Center Innovation Institute and an investor in and advisor to a number of life science, medical device, energy, and digital technology companies. He holds a BA magna cum laude from Yale, where he graduated at 19, and a JD from Harvard Law School.

Anton toutov

Anton Toutov, PhD.

Co-Founder and CSO

Dr. Toutov holds a PhD in organic chemistry from Caltech in the laboratory of Nobel Laureate Robert H. Grubbs, where he held Dow-Resnick, NSERC, and Bristol-Myers Squibb fellowships. Dr. Toutov collectively has over 40 scholarly articles and patent grants and applications to his name spanning the fields of chemical synthesis, clean energy, and drug discovery. Among them is the discovery of a new form of catalysis, which was first published in Nature and was later presented to general audiences in the documentary film Element 19. He is the recipient of the 2016 Demetriades Caltech Thesis Prize, the 2015 Alfred Bader Award for Student Innovation (Sigma-Aldrich Corporation), the 2014 Dow Chemical Sustainability Challenge Grand Prize, and the 2014 Milliken & Co. “Deep Science” award, among others. Dr. Toutov also serves as senior technical advisor to the Gates Foundation-backed Medicines for All Institute, improving access to affordable, high-quality medicines. 

Nove spivack

Nova Spivack


Mr. Spivack is a serial entrepreneur, technology futurist, and co-founder of the in house incubator of Stanford Research Institute (SRI) and Sarnoff Laboratories, which launched SIRI (acquired by Apple). He is the founder and CEO of the early stage science and technology incubator, Magical, and is co-founder and chairman of the Arch Mission Foundation. Previously, Mr. Spivack was CEO of Bottlenose, a leader in real-time data analytics. He founded Radar Networks in 2003, business incubator Lucid Ventures in 2001, and in 1994 he co-founded EarthWeb, Inc., one of the first web start-ups (record-breaking IPO in 1998) and spinout (IPO in 2007). He is also a co-founder or early investor in The Daily Dot, Klout (acquired by Lithium), and a number of applied and life science companies including Space Adventures and Cambrian Genomics. Mr. Spivack is an inventor on nearly 100 granted and pending patents.